Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1991-8-21
|
| pubmed:abstractText |
We correlated polymerase chain reaction (PCR)-detectable BCR-abl fusion transcripts with cytogenetic status in 24 patients with acute lymphocytic leukemia (ALL). Of 10 Philadelphia chromosome negative (Ph-) patients, only one was found to exhibit a BCR-abl fusion transcript. Fourteen patients with Ph+ ALL, including eight in clinical remission, exhibited PCR-detectable BCR-abl rearrangements. A detectable Ph chromosome was present in only five of the eight patients in clinical remission. Of the three cytogenetically negative, BCR-abl-positive patients, two eventually succumbed to post-bone marrow transplantation (BMT) relapse. The third died of early transplant complications. Serial PCR analyses were performed on four Ph+ ALL patients in clinical remission who underwent allogeneic BMT. One patient who was PCR negative on post-BMT days 21 and 75 became PCR-positive on day 116 and died in relapse on day 154. One patient was weakly positive for BCR-abl on day 23, negative on day 56, but died of transplant complications on day 124. Two patients exhibited no post-BMT BCR-abl rearrangements and remain well on days 279 and 371. Our findings suggest that PCR analysis may be useful in the early identification of relapse in patients transplanted for Ph+ ALL.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
0006-4971
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
15
|
| pubmed:volume |
78
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
458-65
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2070081-Adult,
pubmed-meshheading:2070081-Base Sequence,
pubmed-meshheading:2070081-Bone Marrow Transplantation,
pubmed-meshheading:2070081-Child,
pubmed-meshheading:2070081-Chimera,
pubmed-meshheading:2070081-Exons,
pubmed-meshheading:2070081-Female,
pubmed-meshheading:2070081-Fusion Proteins, bcr-abl,
pubmed-meshheading:2070081-Humans,
pubmed-meshheading:2070081-Karyotyping,
pubmed-meshheading:2070081-Male,
pubmed-meshheading:2070081-Molecular Sequence Data,
pubmed-meshheading:2070081-Oligonucleotide Probes,
pubmed-meshheading:2070081-Philadelphia Chromosome,
pubmed-meshheading:2070081-Polymerase Chain Reaction,
pubmed-meshheading:2070081-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:2070081-RNA, Messenger,
pubmed-meshheading:2070081-Transcription, Genetic,
pubmed-meshheading:2070081-Tumor Markers, Biological
|
| pubmed:year |
1991
|
| pubmed:articleTitle |
Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
| pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|